tiprankstipranks
Trending News
More News >

Paradigm Biopharmaceuticals Announces Convertible Notes Issue

Story Highlights
Paradigm Biopharmaceuticals Announces Convertible Notes Issue

Don’t Miss TipRanks’ Half-Year Sale

Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an update.

Paradigm Biopharmaceuticals Limited announced a proposed issue of 27 million convertible notes as part of a new placement. This strategic move is aimed at enhancing the company’s financial flexibility and supporting its ongoing initiatives in the biopharmaceutical sector, potentially impacting its market position and offering opportunities for stakeholders.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for treating diseases. The company is primarily involved in creating innovative solutions for unmet medical needs, with a market focus on advancing healthcare through novel biotechnological applications.

Average Trading Volume: 872,229

Technical Sentiment Signal: Sell

Current Market Cap: A$124.6M

For an in-depth examination of PAR stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1